- News & Features
Researchers found that younger patients, as well as those whose disease was more active, were likelier to stop taking methotrexate due to ineffectiveness.
A systematic review of six studies, published recently in Arthritis Care & Research, evaluates the effectiveness of methotrexate in treating chikungunya.
Younger, thinner rheumatoid arthritis patients, with lower disease activity and better scores on a certain health assessment, have a better chance of achieving remission when combining the tumor-necrosis factor (TNF) inhibitor etanercept (enbrel) with methotrexate induction therapy.
The introduction of biologic disease-modifying anti-rheumatic drugs are associated with a decrease in total knee replacements among RA patients.
New research shows that rheumatoid arthritis patients benefit from participating in personalized, digital health coaching.
Rheumatoid arthritis patients who take opioids or antidepressants are likelier to fracture their bones, according to research presented at the 2017 American College of Rheumatology annual meeting in San Diego.
Three presentations at the American College of Rheumatology annual conference in San Diego addressed new classification criteria for systemic lupus...
Treat-to-target, evidence-based guidelines recommend that rheumatoid arthritis patients be monitored regularly for disease activity and that therapy is adjusted —...
Arthritis patients with resolved hepatitis B infection, who received disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, were unlikely to have the hepatitis B resurface.
The question when the first biologic doesn’t work is: What next?